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Abstract
Background: The pathogenesis and etiology of thoracic aor-
tic aneurysms (TAA) are largely unknown. Preliminary data 
from patients with aortic dissection and abdominal aneu-
rysms suggest a causal link of obstructive sleep apnea (OSA) 
on aortic disease. Objectives: The aim of the study was to 
assess the prevalence of OSA in patients with TAA compared 
to a matched control group. Method: In this prospective par-
allel-cohort study, we 2-to-1 matched 208 patients with ver-
ified TAA (at the aortic sinus and/or ascending aorta) to 104 
controls without TAA according to sex, age, height, weight, 
and left ventricular ejection fraction. All participants under-
went an ultrasound of the thoracic aorta and a level III respi-
ratory polygraphy. OSA was defined as apnea-hypopnea in-
dex ≥5/h. The prevalence of OSA was compared with condi-
tional logistic regression and controlling for the matching 
variables. Results: A total of 312 patients (mean age 65 ± 11 
years, 82% male, mean body mass index 27 ± 4 kg/m2) were 
successfully 2-to-1 matched in the final model. Prevalence of 
OSA was significantly higher in the TAA-group when com-
pared to the matched control group (63 vs. 47%; odds ratio 
1.87 [95% CI 1.05–3.34]; p = 0.03). When applying a higher 
apnea-hypopnea index threshold (≥15/h), the odds ratio in-
creased to 3.25 (95% CI 1.65–6.42; p < 0.001). The median 
apnea-hypopnea index was higher in patients with TAA 
(9.2/h [3.3–20.0] vs. 4.5/h [2.2–11.1], p < 0.001). Conclusions: 
Patients with TAA have a higher prevalence of OSA when 
compared to the general population. Since OSA is effective-
ly treatable and might contribute to the pathogenesis of 
TAA, further longitudinal trials are needed to assess the as-
sociation between OSA and TAA. © 2019 S. Karger AG, Basel
Introduction
A thoracic aortic aneurysm (TAA) is a localized dila-
tion of the thoracic aorta with an incidence rate of ap-
proximately 10 per 100,000 person-years in both sexes 
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[1]. The majority of TAAs are sporadic and occur in as-
sociation with the classical risk factors for atherosclerosis 
(i.e., smoking, arterial hypertension, and hypercholester-
olemia). Nevertheless, these risk factors alone poorly 
predict the incidence of TAA [2]. Although clinically si-
lent, TAA is associated with life-threatening complica-
tions such as thrombosis, dissection, and rupture. The 
cumulative 5-year risk of rupture ranges from 15 to 20% 
and primarily depends on the diameter of the aneurysm 
[1, 3].
Obstructive sleep apnea (OSA) is a sleep-related 
breathing disorder, caused by complete or partial 
obstruction of the upper airway, leading to nocturnal 
apneas and hypopneas. It is estimated, that at least 
20% of males and 10% of females in Western countries 
are affected by asymptomatic OSA [4, 5]. An extensive 
body of literature has described OSA as a causal factor 
in the pathogenesis of vascular dysfunction and arteri- 
al hypertension [6–8]. OSA is a treatable medical con-
dition and the most common therapies effectively 
counteract adverse effects of OSA, such as hypertension 
[7].
Initially, observational studies in patients with Mar-
fan syndrome (a genetic disorder of the connective tis-
sue) reported that the severity of OSA independently 
affects the aortic diameter and has an influence on the 
aortic event-free survival rate [9–11]. Furthermore, 
several cross-sectional studies in the general population 
reported that OSA is highly prevalent among patients 
with abdominal aortic aneurysms [12–14] and dissec-
tions [14–20]. Finally, longitudinal data suggest that se-
vere OSA may contribute to a faster aneurysm expan-
sion [13] and that the gold standard therapy for OSA 
(continuous positive airway pressure therapy) may 
counteract the adverse effects of OSA on the aneurysm 
expansion [21].
According to the literature, there seem to be three 
main mechanisms behind the contribution of OSA to 
aortic disease: (1) increased nocturnal negative intratho-
racic pressure surges leading to stretching of the aorta, 
consecutively leading to its long-term distension; (2) 
arousal-induced sympathetic activation with subsequent 
hypertension; and (3) intermittent hypoxia associated 
with autonomic nervous system activation and conse-
quently increased oxidative stress [6].
Whether there is an association between OSA and 
TAA is currently unknown. We have aimed to address 
this knowledge gap by performing a prospective parallel 
cohort study in patients with and without TAA. 
Methods
Study Design and Participants
The primary outcome was the prevalence of OSA in patients 
with TAA compared to a matched control group. The secondary 
outcome was the association of OSA (reflected by the apnea-hy-
popnea index [AHI]) with thoracic aortic diameter. Patients with 
TAA were enrolled from an ongoing cohort study (ClinicalTrials.
gov Identifier: NCT02204774). Matched controls were recruited 
from the outpatient clinic of the University Hospital Zurich be-
tween January and November 2018. Exclusion criteria for both 
groups were: (1) age < 18 years; (2) continuous positive airway 
pressure therapy for OSA; (3) diagnosis of central sleep apnea; (4) 
relevant use of substances significantly modulating the respira-
tory drive, e.g. therapy with or addiction to morphine derivates 
or alcohol; (5) pregnancy; (6) moderate-to-severe aortic regurgi-
tation; and (7) moderate-to-severe aortic stenosis. Presence of 
TAA was defined as an aortic diameter exceeding the sex-specif-
ic cut-offs at the level of the sinus of Valsalva (≥39 mm for wom-
en, ≥44 mm for men) or the ascending aorta (≥42 mm for wom-
en, ≥46 mm for men) [22]. For each two patients from the TAA 
cohort, one control subject was recruited. The 2-to-1 matching 
was based on variables identified a priori to be of interest. The 
caliper distances for continuous variables in each pair did not 
exceed 25% of the standard deviation of the pooled variable. 
Matching variables included sex (exact), age (±5 years), height 
(±20 cm), weight (±20 kg), and left ventricular ejection fraction 
(±10%). 
Respiratory Polygraphy
Every patient underwent a full ambulatory level III respiratory 
polygraphy (ApneaLink Air; ResMed, San Diego, CA, USA) dur-
ing the habitual sleep time. The setup was as recommended, and 
all raw data were reviewed manually by two trained investigators 
(T.G., P.B.) and scored according to the guidelines by the Ameri-
can Academy of Sleep Medicine recommendations from 2007 
(version A) [23]. OSA was defined as an AHI ≥5/h.
Echocardiography
Echocardiographic studies were performed on a cardiovascular 
ultrasound system (Vivid E9 with XDclear, GE Healthcare, Little 
Chalfont, UK) with a 3.5-MHz transducer. The diameter of the 
aortic sinus (defined as the largest diameter at the sinus of Val-
salva) and the ascending aorta (at the level of the right pulmonary 
artery) were measured in the left parasternal long axis window us-
ing two-dimensional, guided M-mode echocardiography in end-
systole. Every measurement was performed at least three times, 
and data were averaged by the mean. According to the recommen-
dations by the American Society of Echocardiography, the “lead-
ing edge-to-leading edge” technique was applied for all measure-
ments [24]. The left ventricular ejection fraction was calculated 
according to the biplane Simpson’s method.
Blood Pressure Measurement
Blood pressure and heart rate were measured in triplicate with 
a standard digital automatic monitor (Omron Healthcare Com-
pany, Kyoto, Japan) in the sitting position after a period of rest of 
5 min. The average of these three blood pressure measurements 












































































For the primary outcome, a sample size goal of > 300 patients 
(200 cases, 100 controls) was established (α = 0.05, β = 0.2) to detect 
an absolute difference in OSA of 10% between groups, assuming the 
prevalence rate of OSA in the TAA group is similar to those found 
in patients with abdominal aortic aneurysm [13]. As recommended, 
conditional logistic regression adjusted for the matching variables 
was used to compare the prevalence of OSA between groups [26]. 
We used a mixed effects regression analysis to compare continuous 
variables assessing OSA severity, adjusted for the matching variables 
and accounting for the cluster of each 2-to-1-matched pair as a ran-
dom effect. A two-sided p value of < 0.05 was considered statisti-
cally significant for all reported tests. Statistical analysis was per-
formed with STATA Version 15 (StataCorp LP, College Station, TX, 
USA). Results are presented as mean (±standard deviation of the 
means) or median (interquartile range) as appropriate.
Results
Patient Characteristics
The matching process yielded 208 patients with TAA, 
2-to-1 paired to 104 matched control subjects. The ini-
tially calculated sample size was surpassed by 4% (n = 12). 
The subjects were predominantly male (81.7%) and Cau-
casian (98%). The study flow chart is depicted in Figure 
1. No statistically significant confounders were present 
for the matching variables. As expected, patients with 
TAA had a higher blood pressure (in terms of both, the 
pre-listed diagnoses and measurements performed in our 
study) and were significantly more often prescribed 
β-adrenoreceptor antagonists. For summary statistics 
and background information, see Tables 1 and 2. In pa-
tients with TAA, the aneurysm was present at the aortic 
sinus (32%) and the ascending aorta (25%) or both sites 
(43%) according to the prespecified values.
Primary Outcome
Sleep study data were available for all study partici-
pants, after 24 (TAA group) and 11 (control group) pa-
tients successfully repeated the testing due to initially in-
sufficient data (< 4 h of sleep or technical issues). The un-
adjusted median AHI (Fig. 2) was higher in patients with 






























No answer (n = 422)
Declined (n = 191)
CPAP therapy (n = 33)















Did not meet inclusion criteria
due to error in measurement,
aortic diameter too small
(n = 10)
Analysis for primary outcome
104 pairs matched 2-to-1 for age (±5 years), height (±20 cm),
weight (±20 kg), and ejection fraction (±10%) (n = 312)
TAA cohort
(n = 208)
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TAA when compared to controls (9.2/h [3.3–20.0] vs. 
4.5/h [2.2–11.1]; p < 0.001). In patients with TAA, OSA 
prevalence (defined as an AHI of ≥5/h) was 63 versus 47% 
in the matched control group (odds ratio 1.87 [95% CI 
1.05–3.34]; p = 0.033) adjusted for the matching variables 
age, sex, left ventricular ejection fraction, height, and 
weight. When applying a higher AHI threshold for OSA 
diagnosis (AHI ≥15/h), the odds ratio increased to 3.25 
(95% CI 1.65–6.42; p < 0.001). For the cut-off value of AHI 
≥30/h, however, this association was no longer statistical-
ly significant (OR 3.21, 95% CI 0.68–15.11, p = 0.141) pri-
marily due to the decreased number of observations in this 
range. Unadjusted prevalence data are presented in Table 
3. In the mixed effects model, age and weight were statisti-
cally significant direct predictors of a high AHI value (both 
p < 0.001). Sex, height, and left ventricular ejection fraction 
were not associated with OSA severity (p > 0.05). 
Secondary Outcome
The raw diameters (in cm) of the aortic sinus and the 
ascending aorta were associated with the raw AHI 
(events/h) in the TAA group (coefficient 6.5 [95% CI 1.3–
11.8], p = 0.01 and coefficient 7.3 [95% CI 1.8–12.9] p = 
0.01 respectively). However, further adjustments for all 
the matching variables (including an interaction term for 
weight and age) unmasked this association as insignifi-
cant (p > 0.05). This also applies to other variables from 
the sleep data (e.g., the oxygen desaturation index, the 
time spent below a peripheral oxygen saturation of 90%, 
mean peripheral oxygen saturation).







Male sex, n (%) 170 (81.7) 85 (81.7) –
Age, years 65.94±10.49 64.43±11.74 0.25
Height, cm 174.83±8.19 173.41±8.56 0.16
Weight, kg 82.12±13.01 80.81±12.11 0.39
BMI, kg/m2 26.89±4.19 26.89±3.83 1.00
Neck circumference, cma 39.26±3.28 39.83±3.87 0.17
Hip circumference, cm 99.96±11.81 102.08±7.54 0.10
Waist circumference, cm 102.16±9.23 99.96±12.72 0.09
Systolic blood pressure (office), mm Hgb 132.49±27.19 121.30±15.00 <0.01
Diastolic blood pressure (office), mm Hgb 81.86±11.78 77.71±9.78 <0.01
Heart rate (office), min–1 69.27±11.63 71.05±13.52 0.23
Comorbidities
Smoker, n (%) 29 (14.1) 14 (13.5) 0.88
Pack years of smoking, pack years 17.99±25.57 14.90±20.74 0.30
Arterial hypertension, n (%) 155 (75.2) 51 (49.0) <0.01
Dyslipidemia, n (%) 121 (59.6) 62 (59.6) 1.00
Diabetes mellitus type 2, n (%) 14 (7.2) 11 (10.8) 0.29
History of stroke, n (%) 30 (14.6) 11 (10.7) 0.34
History of coronary artery disease, n (%) 45 (22.0) 35 (34.0) 0.02
Abdominal aortic aneurysm, n (%) 10 (4.9) 2 (1.9) 0.21
Renal deficiency, n (%) 19 (9.2) 13 (12.6) 0.36
COPD, n (%) 15 (7.3) 3 (2.9) 0.12
Atrial fibrillation, n (%) 43 (20.9) 18 (17.5) 0.48
Marfan syndrome, n (%) 1 (0.5) 0 (0) 0.48
Turner syndrome, n (%) 0 (0) 0 (0) –
Bicuspid valves, n (%) 14 (7.8) 1 (1) 0.01
COPD, chronic obstructive pulmonary disease; BMI, body mass index; TAA, thoracic aortic aneurysm. 
a Measured between the mid-cervical spine and the mid-anterior neck. b Office blood pressure: measured in 












































































In our study, the systolic and diastolic office blood 
pressure was not associated with the AHI (events/h) (co-
efficient 0.02 [95% CI –0.03 to 0.08], p = 0.44, and coef-
ficient 0.10 [95% CI –0.30 to 0.24], p = 0.12, respectively) 
and neither was the diagnosis of arterial hypertension 
(coefficient 2.4 [95% CI –0.78 to 5.55], p = 0.14). Also, no 
significant association between the AHI and low-density 
lipoprotein could be established (data not shown).
Discussion
To our knowledge, this is the first study to report a 
higher prevalence of OSA in patients with TAA when 
compared to a matched control group. We found an ap-
proximately 1.3-fold increased prevalence of OSA in pa-
tients with TAA when compared to a matched control 
group. 
Sixty-three percent of patients with TAA had an AHI 
of ≥5/h, which was in line with previously published 







Cholesterol, mmol/L 4.63±1.19 4.34±1.17 0.09
Triglycerides, mmol/L 1.59±0.82 1.78±1.69 0.24
High-density lipoprotein, mmol/L 1.40±0.50 2.53±9.64 0.13
Low-density lipoprotein, mmol/L 2.62±1.09 2.30±1.07 0.04
Diabetes mellitus type 2, n (%) 14 (7.2) 11 (10.8) 0.29
HbA1c, % 5.65±0.64 5.68±1.11 0.83
Medication
β-Adrenoreceptor antagonists, n (%) 107 (52.2) 38 (36.5) <0.01
α-Adrenoreceptor antagonists, n (%) 11 (5.4) 6 (5.8) 0.88
Calcium channel blockers, n (%) 50 (24.5) 16 (15.4) 0.06
ACE inhibitors, n (%) 70 (34.1) 36 (34.6) 0.93
Angiotensin II receptor blocker, n (%) 51 (24.9) 17 (16.3) 0.09
Diuretics, n (%) 65 (31.7) 24 (23.3) 0.12
Aldosterone, n (%) 7 (3.4) 7 (6.7) 0.19
Total number of antihypertensives <0.01
0 antihypertensive drugs, n (%) 36 (17.3) 36 (34.6)
1 antihypertensive drug, n (%) 54 (26.0) 26 (25.0)
2 antihypertensive drugs, n (%) 66 (31.7) 19 (18.3)
3 antihypertensive drugs, n (%) 34 (16.3) 14 (13.5)
4 antihypertensive drugs, n (%) 17 (8.2) 7 (6.7)
5 antihypertensive drugs, n (%) 1 (0.5) 2 (1.9)
Statins, n (%) 116 (56.6) 54 (51.9) 0.44
Oral antidiabetics, n (%) 10 (4.9) 7 (6.7) 0.50
Insulin, n (%) 3 (1.5) 2 (1.9) 0.76
Phenprocoumon, n (%) 50 (24.4) 11 (10.6) <0.01
New oral anticoagulants, n (%) 14 (6.8) 12 (11.5) 0.16
Aspirin, n (%) 78 (38.0) 38 (36.5) 0.80
Dual antiplatelet therapy, n (%) 16 (7.8) 10 (9.6) 0.59
Echocardiography
Left ventricular ejection fraction, % 57.54±8.50 55.68±10.19 0.10
Aortic sinus, cm 4.51±0.56 3.61±0.39 <0.01
Ascending aorta, cm 4.50±0.46 3.58±0.42 <0.01
Left ventricular myocardial mass index, g/m2 100.5±32.1 80.19±24.18 <0.01
Left atrial end-systolic dimension, cm 4.00±0.82 3.94±0.75 0.58
Left ventricular end-systolic dimension, cm 3.2±0.7 3.19±0.84 0.69







































































Gaisl et al.Respiration 2020;99:19–2724
DOI: 10.1159/000502892
prevalence data on OSA among patients with an abdom-
inal aortic aneurysm [13]. Compared to the study of Ma-
son et al. [13], which investigated an anthropometrically 
similar population with abdominal aortic aneurysms (68 
± 6 years old, BMI 28 ± 4 kg/m2, 91% male, n = 127), we 
report almost identical results regarding the AHI (mean 
13.8 ± 16.6 vs. 13.6 ± 13.4 and prevalence of 64 vs. 63% 
in our study). On the other hand, the prevalence of OSA 
among patients with TAA in our study tends to be lower 
than the rates from the five previously described cohorts 
encompassing patients after aortic dissections, ranging 
from 61 to 82% [15–18, 20]. Still, to our knowledge, our 
TAA sample represents the largest cohort studied so far 
in aortic disease [13, 15–18, 20]. Most importantly, all 
studies investigating the impact of OSA on the aorta 
which included a control-group, reported a higher prev-
alence of OSA in the aortic disease group [14, 16, 17, 20]. 
Our study confirms this relationship for patients with 
TAA and adds further evidence to the association be-
tween OSA and aortic disease. Our study delivers further 
support to the association between OSA and aortic dis-
ease in general. So far, six cross-sectional cohorts have 
described an association between the severity of OSA 
and the diameter of the aorta [10, 27–31]. Although we 
included this association as a secondary outcome in our 
study, we were not able to reproduce these previous find-
ings after adjusting for age, weight, sex, and left ventric-
ular ejection fraction. Severe OSA was not independent-
ly associated with a greater aortic diameter. This result 
was, however, in line with two other studies on this top-
ic, which also accounted for the same confounders [32, 
33].
The underlying mechanisms by which OSA might 
contribute to aortic disease are currently subject to in-
vestigation [6]. We identified three studies, describing 
distensions of the thoracic aorta during simulated ob-
structive apneas, leading to additional dilatory force 
measured via an aortic catheter [34–36]. Another study 
measured the nocturnal negative intrathoracic pressure 
surges in patients with untreated OSA; these could re-
portedly peak up to –147 cm H2O [37]. It is plausible to 
assume that such repetitive, negative pressure surges 
promote a long-term distension of the aorta [6]. Addi-
tionally, the prolonged sympathetic activation with sub-
sequent blood pressure elevation in patients with OSA 
may also play a crucial role. In OSA, arterial blood pres-
sure is particularly elevated during sleep, and nocturnal 
non-dipping patterns (diminished night-time blood 
pressure reductions) are especially prominent [38]. Me-
ta-analyses have also consistently demonstrated the 
long-term blood pressure rises in OSA, and arterial hy-
pertension is one of the main risk factors associated with 
the incidence of TAA [2, 7]. Finally, it is also plausible 
that OSA-induced overall increase in oxidative stress 
(e.g., in the endothelium) further contributes to aortic 
remodeling [6].
As expected, patients with TAA displayed a signifi-
cantly higher prevalence of bicuspid aortic valves and a 
higher left ventricular myocardial mass index in our co-
hort. This is in line with previous population-based stud-
ies, where bicuspid valves are a risk factor for TAA [39]. 
In addition, untreated OSA over a long period is associ-
ated with the development of left ventricular hypertrophy 
[40]. However, in our study, we could not find a statisti-
cally significant association in a post hoc analysis between 
AHI/ODI, systolic/diastolic blood pressure versus the left 
ventricular myocardial mass index or the bicuspid valves 
vs. the AHI, respectively (data not shown). Thus, it is un-
likely that these parameters might have influenced our 
primary outcome. It is important to note that the pres-
ence of arterial hypertension can also contribute to the 
increase in TAA and left ventricular myocardial mass in-
dex, respectively, and therefore might possibly explain 
the differences in Table 1 irrespective of the presence of 
OSA [41].
+ + +++++++++++++++++++




















Fig. 2. Apnea-hypopnea index (AHI) by groups. Conventional 
thresholds for the AHI (5, 15, and 30) are marked with a dashed 
line. The median of each group is indicated with the black bar. The 













































































One limitation of our study was the fact that we used 
level III respiratory polygraphy in a single overnight 
study to measure OSA severity, rather than the gold stan-
dard polysomnography. However, a level III respiratory 
polygraphy demonstrated a good overall agreement with 
polysomnography in terms of AHI and oxygen desatura-
tion indices and was therefore proven to be non-inferior 
in the clinical setting [42]. Furthermore, we did not per-
form a 24-h ambulatory blood pressure monitoring, 
which would be more precise [25], and the limitations of 
ultrasound did not allow for inclusion of TAA at the aor-
tic arch and descending aorta, which represent approxi-
mately 50% of all TAA [40]. The high proportion of males 
in our study may be regarded as a limitation when it 
comes to the generalizability of the data. Finally, it is not-
ed that our design of the study does not allow establishing 
any causal relationships between OSA and TAA.
Conclusions
The prevalence of OSA is higher among patients with 
TAA than in the general population. Since OSA is effec-
tively treatable and might contribute to the pathogenesis 
of TAA in several ways, further longitudinal studies as-
sessing the relationship between the two are necessary. In 
the future, this might result in recommendations of 
screening for OSA among patients suffering from spe-
cific subtypes of aortic diseases. 
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Apnea hypopnea index, h–1 9.2 (3.3–20.0) 4.5 (2.2–11.1) <0.01
Apnea hypopnea index ≥5 h–1 131 (63%) 49 (47%) <0.01
Apnea hypopnea index ≥15 h–1 71 (34%) 16 (15%) <0.01
Apnea hypopnea index ≥30 h–1 27 (13%) 8 (8%) 0.16
Oxygen desaturation index (4%), h–1 13.52±12.65 9.04±12.72 <0.01
Total time in bed, h 6.32±1.51 6.42±1.70 0.82
Respiratory rate, min–1 14.78±2.58 14.23±2.92 0.09
Epworth Sleepiness Scale, points 6.29±3.88 6.82±3.67 0.25
Sleep data were derived from one night with level III respiratory polygraphy and scored according to the 
American Society of Sleep Medicine criteria from 2007 (version A) [23]. Data are reported as mean (SD) or 
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